Transducin-beta-like 1 receptor 1 (TBL1XR1), encoded on chromosome 3 at q26.32, is a WD40 domain-containing protein with roles
in both transcriptional activation and repression. Missense and loss-of-function sequence
variants in TBL1XR1 have been identified in individuals with autism, developmental delay, and/or intellectual
disability, as well as Pierpont syndrome, characterized by distinctive facial features,
global developmental delay, learning disability, and palmer and plantar fat pads.
Additionally, microdeletions involving TBL1XR1 are associated with autosomal dominant intellectual disability with nonspecific dysmorphic
facial features. Recently, there has been one report of four individuals with microduplications
encompassing TBL1XR1 that presented clinically with speech and developmental delay, learning disability,
or mild intellectual disability. The copy number gain was de novo in one individual and was shown to segregate in three affected individuals in another
family. Although the duplications are predicted to increase the dosage of TBL1XR1, these individuals were phenotypically similar to microdeletion patients. Furthermore,
there are five individuals in the DECIPHER database with autism, delay, and intellectual
disability with focal duplications of TBL1XR1. The duplications were shown to be de novo in two of the individuals and segregated in a mother and daughter in another family.
Here, we present an additional patient with speech and developmental delay, concern
for autism, and a maternal family history of learning difficulties. Using the Affymetrix
CytoScan HD microarray system, we identified a heterozygous 288 kb gain of 3q26.32,
involving only the TBL1XR1 gene. Parental testing is pending. This is the smallest copy number gain reported
thus far that still contains the entire coding region of the TBL1XR1 gene; however, the patient's clinical presentation closely resembles previous reports.
Although duplications of this region of chromosome 3 appear to be rare, this case
provides further evidence for TBL1XR1 triplosensitivity.
To read this article in full you will need to make a payment
© 2021 Published by Elsevier Inc.